Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by ...

Operator: Good morning, and welcome to the Syros Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At ...

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial ...

Syros Pharmaceuticals ( (SYRS)) has released its Q3 earnings. Here is a breakdown of the information Syros Pharmaceuticals presented to its investors. Syros Pharmaceuticals, Inc., a ...